Latest Commercialisation Strategy News

Hazer Group has entered a binding six-year strategic alliance with global engineering leader KBR to exclusively market and license its methane pyrolysis technology, targeting the ammonia and methanol sectors. This partnership aims to accelerate commercialisation, expand global reach, and materially de-risk Hazer’s business plan.

Skin Elements Limited advances its natural biotechnology products with ECO-Nurture trials concluding and SuprCuvr disinfectant gaining traction, supported by a successful $656k capital raise.

Wide Open Agriculture has inked an exclusive 18-month distribution agreement with Univar Solutions China to market its lupin protein products, marking a strategic push into the lucrative Chinese plant-based protein sector.

InteliCare Holdings has secured a binding agreement to trial its AI-driven platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy within Victoria’s aged care sector.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.

Prospect Resources has declared a maiden JORC-compliant copper resource of 107.2 million tonnes at 0.5% copper at its Mumbezhi Project in Zambia, alongside securing a strategic A$15.2 million investment from First Quantum Minerals. This milestone advances the project towards development with Phase 2 drilling planned for Q2 2025.

Provaris Energy has launched a capital-lite revenue model designed to generate early cash flow with minimal capital expenditure, alongside securing a major hydrogen supply agreement with Uniper Global Commodities. The company targets first hydrogen deliveries by early 2029, advancing its position in Europe's hydrogen supply chain.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Calix Limited has successfully closed its Share Purchase Plan, raising $2.1 million to complement a prior $20 million institutional placement, strengthening its balance sheet to advance key environmental technology projects.

Dreadnought Resources reports robust exploration results including high-grade gold at Mangaroon and niobium at Gifford Creek, alongside new joint ventures and asset sales that position the company for growth.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.